ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Rating) saw a significant decline in short interest in November. As of November 15th, there was short interest totalling 502,200 shares, a decline of 12.5% from the October 31st total of 573,700 shares. Currently, 4.0% of the shares of the company are short sold. Based on an average daily volume of 66,900 shares, the short-interest ratio is presently 7.5 days.
Analyst Upgrades and Downgrades
ANIP has been the topic of several analyst reports. HC Wainwright initiated coverage on ANI Pharmaceuticals in a research report on Wednesday, September 7th. They set a “buy” rating and a $50.00 target price on the stock. TheStreet raised ANI Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Wednesday, August 17th. Raymond James raised their price target on ANI Pharmaceuticals from $47.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, August 9th. Finally, StockNews.com initiated coverage on ANI Pharmaceuticals in a report on Wednesday, October 12th. They set a “hold” rating on the stock. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.00.
ANI Pharmaceuticals Price Performance
NASDAQ:ANIP traded down $0.02 on Friday, reaching $38.83. 63,998 shares of the company’s stock traded hands, compared to its average volume of 75,912. ANI Pharmaceuticals has a 12 month low of $22.31 and a 12 month high of $51.69. The company has a quick ratio of 2.62, a current ratio of 3.79 and a debt-to-equity ratio of 0.92. The stock has a 50-day simple moving average of $36.39 and a 200-day simple moving average of $33.67. The firm has a market cap of $678.36 million, a PE ratio of -8.67 and a beta of 1.05.
Institutional Investors Weigh In On ANI Pharmaceuticals
Several large investors have recently made changes to their positions in ANIP. Commonwealth Equity Services LLC increased its holdings in shares of ANI Pharmaceuticals by 6.7% in the first quarter. Commonwealth Equity Services LLC now owns 12,243 shares of the specialty pharmaceutical company’s stock worth $344,000 after purchasing an additional 765 shares during the last quarter. Texas Permanent School Fund increased its holdings in shares of ANI Pharmaceuticals by 15.6% in the first quarter. Texas Permanent School Fund now owns 9,021 shares of the specialty pharmaceutical company’s stock worth $254,000 after purchasing an additional 1,214 shares during the last quarter. Qube Research & Technologies Ltd bought a new stake in shares of ANI Pharmaceuticals in the first quarter worth about $321,000. Brown Advisory Inc. increased its holdings in shares of ANI Pharmaceuticals by 23.3% in the first quarter. Brown Advisory Inc. now owns 17,634 shares of the specialty pharmaceutical company’s stock worth $496,000 after purchasing an additional 3,333 shares during the last quarter. Finally, Swiss National Bank increased its holdings in shares of ANI Pharmaceuticals by 7.1% in the first quarter. Swiss National Bank now owns 27,000 shares of the specialty pharmaceutical company’s stock worth $759,000 after purchasing an additional 1,800 shares during the last quarter. 56.85% of the stock is owned by institutional investors.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ANI Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and ANI Pharmaceuticals wasn’t on the list.
While ANI Pharmaceuticals currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Read More: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Sees Significant Decrease in Short Interest